Teleflex (TFX) Stock Forecast & Price Target

Teleflex is positioned for upside because its Interventional segment is stabilizing, with integration headwinds improving materially as misdirected orders fell below 1%, distributor transitions are ~87% complete, and open sales territories are down 63% from peak levels. The company also strengthened its balance sheet, cutting net leverage to 1.4x from 2.8x after the OEM divestiture and $700MM Term Loan A-2 payoff, while management targets ~23% adjusted operating margin within 12 months of the AC/IU close and continues disciplined capital allocation through R&D, M&A, debt repayment, and shareholder returns. Longer term, Teleflex’s growth setup is supported by EZPLAZ, the FDA Breakthrough-designated Freesolve platform, and renewed R&D investment at ~8% of revenue, which together could sustain mid-single digit revenue growth and drive margin and EPS expansion into 2027 and beyond.

Teleflex is viewed negatively because its core growth engine is slowing, with management cutting FY26 pfcc revenue growth guidance to 3.5-4.5% from 4.5-5.5% after an elongated Biotronik integration timeline, implying interventional headwinds could keep growth in the low-single digits. The bear case also assumes organic revenue growth of less than 4% from disappointing product launches and market share loss, while slower-than-expected adoption of key products and greater macro pressure could further restrain upside. Although adjusted operating margin is reiterated at about 19% and 2027 steady-state targets are closer to 23%, margin deterioration, weak execution, and integration risk leave earnings quality and valuation vulnerable.